Renibus Therapeutics
Phase 3Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases.
Founded
2018
Focus
Small Molecules
About
Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases.
Funding History
2Total raised: $85M
Series B$55MCormorant Asset ManagementSep 15, 2022
Series A$30MPerceptive AdvisorsMar 15, 2021
Company Info
TypePrivate
Founded2018
LocationSouthlake, United States
StagePhase 3
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile